By Elisa Pérez (Gynaecologist – Reg. No. 203311163).
When a woman is diagnosed with breast cancer, she will probably not think about her future fertility, as the fear of this disease and how it will evolve will occupy all her thoughts.
However, it is very important to be clear about whether we would like to have the option of becoming mothers once the treatment is over, as the effects of chemotherapy can be devastating for our reproductive capacity. Oocyte cryopreservation plays a key role here and can help women overcoming cancer to achieve pregnancy.
According to the Observatorio del Cáncer of the la Asociación Española Contra el Cáncer, 34740 people were diagnosed with breast cancer in Spain in 2022, mainly women. In fact, it is the most common cancer among Spanish women and the most common cancer worldwide, and it is estimated that up to 1 in 8 women will suffer from it in their lifetime.
The survival rate, however, is over 85% within 5 years of overcoming it, although it can have negative effects on women's fertility. Chemotherapy or pelvic radiotherapy treatments can damage the ovaries and reduce the number of oocytes, so it is advisable to consult a specialist about the possibility of freezing oocytes before starting treatment.
X-ray of a woman with breast cancer
It depends on many factors, but pregnancy is possible. The first step is to undergo a medical evaluation in which a specialist can check your health and your ovarian function after treatment. In addition, it is advisable to wait for a period of time after finishing the cancer treatment and starting to get pregnant, usually around two years, which is the time to monitor a possible reappearance of the cancer and to ensure that the body has recovered properly.
It should be noted that not all women who undergo this type of treatment suffer permanent infertility. In fact, it is estimated that the rate of recovery of ovarian function can be between 20% and 70% depending on the type of chemotherapy used to fight the cancer. If a natural pregnancy is not possible, there are different assisted reproduction methods that can help the process, such as in vitro fertilisation (IVF), oocyte donation or embryo adoption.
Immediately after the diagnosis of cancer and before starting chemotherapy treatment, the possibility of preserving fertility through oocyte vitrification should be considered. It is a technique in which oocytes are retrieved before they can be damaged by the treatment and preserved for use once the disease is overcome. According to data from the Sociedad Española de Fertilidad (SEF), almost 40% of oocyte vitrification cycles during 2021 were due to medical reasons.
The rest were for social reasons. It is a safe technique that is highly effective in women who have decided to postpone the moment of becoming mothers and want to do so with their own oocytes, avoiding oocyte donation.

Whether gestation is natural or through assisted reproduction, pregnancy after breast cancer is safe for both mother and baby. Moreover, current data indicate that pregnancy does not increase the risk of breast cancer recurrence, although it is important to have a complete evaluation with the oncologist before becoming pregnant and an adequate medical follow-up during pregnancy to confirm that everything is progressing perfectly.
Santiago Moragón, Raimondo Di Liello, Begoña Bermejo, Cristina Hernando, Ernesto Olcina, Isabel Chirivella, Ana Lluch, Juan Miguel Cejalvo, María Teresa Martínez.
Fertility and breast cancer: A literature review of counseling, preservation options and outcomes.
.
2021;
103461
Revisión sobre la fertilidad en pacientes con cáncer de mama, incluyendo asesoramiento reproductivo, preservación de la fertilidad mediante criopreservación de ovocitos y embriones y seguridad del embarazo después del cáncer:
https://pubmed.ncbi.nlm.nih.gov/34461268/
Yeon Hee Hong, Changhee Park, Haerin Paik, Kyung-Hun Lee, Jung Ryeol Lee, Wonshik Han, Seho Park, Seockhoon Chung, Hee Jeong Kim.
Fertility Preservation in Young Women With Breast Cancer: A Review.
.
2023;
221-242
Revisión sobre el riesgo de infertilidad asociado a los tratamientos del cáncer de mama y las principales opciones de preservación de la fertilidad, incluyendo criopreservación de ovocitos, embriones y tejido ovárico:
https://pubmed.ncbi.nlm.nih.gov/37387349/
Alessia Romito, Sonia Bove, Ilaria Romito, Drieda Zace, Ivano Raimondo, Simona Maria Fragomeni, Pierluigi Maria Rinaldi, Domenico Pagliara, Antonella Lai, Fabio Marazzi, Claudia Marchetti, Ida Paris, Gianluca Franceschini, Riccardo Masetti, Giovanni Scambia, Alessandra Fabi, Giorgia Garganese.
Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis.
.
2021;
704
Revisión sistemática y metaanálisis sobre el efecto de la quimioterapia en la reserva ovárica de mujeres con cáncer de mama, evaluando especialmente los cambios en los niveles de hormona antimülleriana (AMH):
https://pubmed.ncbi.nlm.nih.gov/34442350/
Matteo Lambertini, Eva Blondeaux, Marco Bruzzone, Marta Perachino, Richard A. Anderson, Evandro de Azambuja, Philip D. Poorvu, Hee Jeong Kim, Cynthia Villarreal-Garza, Barbara Pistilli, Ines Vaz-Luis, Cristina Saura, Kathryn J. Ruddy, Maria Alice Franzoi, Chiara Sertoli, Marcello Ceppi, Hatem A. Azim Jr, Frederic Amant, Isabelle Demeestere, Lucia Del Mastro, Ann H. Partridge, Olivia Pagani, Fedro A. Peccatori.
Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis.
.
2021;
3293-3305
Revisión sistemática y metaanálisis sobre la posibilidad de embarazo después del cáncer de mama, sus resultados reproductivos y la seguridad materna, fetal y oncológica del embarazo posterior:
https://pubmed.ncbi.nlm.nih.gov/34197218/